New scan may reveal hidden Alzheimer's in stroke survivors
NCT ID NCT02813434
First seen Jun 13, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This study tested whether a special PET scan using florbetapir can help doctors figure out why some people develop memory and thinking problems after a stroke. The scan looks for amyloid plaques, a hallmark of Alzheimer's disease. Researchers studied 92 adults aged 40 to 80 who had a stroke and later experienced cognitive issues. The goal was to see how often Alzheimer's might be the underlying cause, which could guide better diagnosis and care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Amiens
Amiens, 80054, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
florbetapir (a radioactive tracer for PET scans)
What this could lead to
If successful, this could help doctors better identify whether Alzheimer's disease is causing cognitive decline after a stroke, leading to more targeted care.
What could go wrong
This is a completed Phase 3 study with 92 participants, so results are available but may not apply to all stroke survivors. The scan is for diagnosis only, not treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.